Pulse Biosciences (Pulse Biosciences) Cash-to-Debt : 4.85 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Pulse Biosciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Pulse Biosciences's cash to debt ratio for the quarter that ended in Dec. 2023 was 4.85.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Pulse Biosciences could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Pulse Biosciences's Cash-to-Debt or its related term are showing as below:

PLSE' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.81 Med: 5002.43 Max: No Debt
Current: 4.85

During the past 10 years, Pulse Biosciences's highest Cash to Debt Ratio was No Debt. The lowest was 0.81. And the median was 5002.43.

PLSE's Cash-to-Debt is ranked better than
63.46% of 862 companies
in the Medical Devices & Instruments industry
Industry Median: 2.03 vs PLSE: 4.85

Pulse Biosciences Cash-to-Debt Historical Data

The historical data trend for Pulse Biosciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Pulse Biosciences Cash-to-Debt Chart

Pulse Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

3.78

1.80

2.54

0.81

4.85

Pulse Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															0.81	0.72	6.11	5.37	4.85

Competitive Comparison of Pulse Biosciences's Cash-to-Debt

For the Medical Instruments & Supplies subindustry, Pulse Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pulse Biosciences's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pulse Biosciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Pulse Biosciences's Cash-to-Debt falls into.

Pulse Biosciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Pulse Biosciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	44.365	/	(1.058	+	8.086)
	=	4.85

Pulse Biosciences's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	44.365	/	(1.058	+	8.086)
	=	4.85

Pulse Biosciences (NAS:PLSE) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Pulse Biosciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Pulse Biosciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Pulse Biosciences (Pulse Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulse Biosciences Inc (NAS:PLSE) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

6L8:Germany

Address

3957 Point Eden Way, Hayward, CA, USA, 94545

Website

https://www.pulsebiosciences.com

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.

Executives

Robert W Duggan	director, 10 percent owner	611 SOUTH FORT HARRISON AVE, SUITE 306, CLEARWATER FL 33756
Kevin Patrick Danahy	officer: Chief Commercial Officer	50 TEABERRY LANE, BRAINTREE MA 02184
Mitchell E. Levinson	director	3957 POINT EDEN WAY, HAYWARD CA 94545
Manmeet Singh Soni	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Van Den Broek Richard	director	73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830
Maky Zanganeh	director	51 ADAM WAY, ATHERTON CA 94027
Sandra A. Gardiner	officer: CFO & EVP Admin. and Finance	CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Shelley D Spray	director	C/O PULSE BIOSCIENCES, INC., 3957 POINT EDEN WAY, HAYWARD CA 94545
Laureen Debuono	director
Ed Ebbers	officer: EVP & GM, Dermatology	3957 POINT EDEN WAY, HAYWARD CA 94545
Kenneth A Clark	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE., SUNNYVALE CA 94085
Fogarty Thomas J M D	director	C/O VENTURE LAW GROUP, 2800 SAND HILL RD STE 270, MENLO PARK CA 94025
Thierry B. Thaure	director	3957 POINT EDEN WAY, HAYWARD CA 94545
Robert J. Greenberg	director	12744 SAN FERNANDO ROAD, BLDG. 3, SYLMAR CA 91342
Brian B Dow	officer: CFO & SVP Admin. and Finance	5675 GIBRALTAR AVENUE, PLEASANTON CA 94588